HCM
JSPR icon

Highbridge Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Highbridge Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-74
Closed -$3K – 714
2022
Q1 		$3K Buy
+74
New +$3.33K ﹤0.01% 660

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Highbridge Capital Management's JSPR Position: Q2 2022 in Review

Highbridge Capital Management sold out of Jasper Therapeutics (JSPR) in Q2 2022, closing a stake of 74 shares — an estimated $3K sold.

Highbridge Capital Management first reported a position in JSPR in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 23 funds tracked by Wall St. Rank hold JSPR as of Q2 2022.

  • Highbridge Capital Management reported no remaining Jasper Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Highbridge Capital Management sold 74 Jasper Therapeutics shares in Q2 2022, an estimated $3K.
  • Highbridge Capital Management first reported a position in Jasper Therapeutics in Q1 2022 and held it in 1 quarter.
  • Highbridge Capital Management's Jasper Therapeutics position peaked at $3K in Q1 2022.
  • 23 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2022.

Based on Highbridge Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.